Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]leucine is a radiolabeled amino acid used as a positron emission tomography (PET) tracer for the quantitative measurement of regional rates of cerebral protein synthesis in vivo. The compound consists of the essential amino acid leucine labeled with the positron-emitting isotope carbon-11. After intravenous administration, [11C]leucine crosses the blood-brain barrier and is incorporated into proteins during protein synthesis. PET imaging with [11C]leucine enables non-invasive assessment of brain protein metabolism and has been used in research on neurodegenerative diseases such as Alzheimer's disease and in studies investigating memory formation. The mechanism involves uptake by amino acid transporters followed by incorporation into newly synthesized proteins, allowing quantification of protein synthesis rates in specific brain regions[4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]leucine.